Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.69 |
| ▸ | DRD3 | P35462 | 4/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | DRD2 | P14416 | 3/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.63 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.63 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571230 | 0.85 | OPRL1 (0.69) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL5925340 | 0.84 | OPRK1 (0.78) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL13913516 | 0.84 | OPRM1 (0.67) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| Hydrochloric Acid SCHEMBL5925304 | 0.84 | OPRL1 (0.68) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL5248981 | 0.83 | OPRL1 (0.70) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL10736433 | 0.82 | OPRL1 (0.75) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL5248548 | 0.81 | OPRL1 (0.73) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL5925337 | 0.80 | OPRL1 (0.69) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL7757086 | 0.80 | OPRL1 (0.72) | OPRL1OPRM1OPRK1OPRD1DRD3 | |
| SCHEMBL7847623 | 0.80 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392687-B1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-1392687-B1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20060178390-A1 | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JORDAN ALFONZO | 2006-08-10 | — | — | US | disclosed |
| US-7053101-B2 | 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JORDAN ALFONZO | 2006-05-30 | — | — | US | disclosed |
| US-20050004154-A1 | 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JORDAN ALFONZO (US) | 2005-01-06 | — | — | US | disclosed |
| US-6777421-B2 | TREATING A CONDITION SELECTED FROM THE GROUP CONSISTING OF ANXIETY, DEPRESSION, SUBSTANCE ABUSE, NEUROPATHIC PAIN, ACUTE PAIN, MIGRAINE, ASTHMA, COUGH AND IMPROVED COGNITION, IN A SUBJECT IN NEED THEREOF COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1392687-A1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | disclosed |
| WO-2002083673-A1 | 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004154-A1 | 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | OPRL1, CALCRL, OPRK1 | OPRL1 1/4885OPRM1 10/4885OPRK1 3/4885 |
| US-20060178390-A1 | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, OPRK1, CALCRL | OPRL1 1/4885OPRM1 8/4885OPRK1 2/4885 |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, GPR4, GPR174 | OPRL1 1/4885OPRM1 8/4885OPRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.